MedicalResearch.com Interview with:
Yun Gong, M.D.
Associate Professor
Department of Pathology, Unit 53
M D Anderson Cancer Center
Houston, TX 77030
MedicalResearch.com: What are the main findings of the study?
Dr. Gong: Androgen receptor (AR) was positive in 39% of the inflammatory breast cancer (IBC) tumors, approximately one-third of estrogen receptor (ER)-negative and progesterone receptor (PR)-negative tumors and 42.6%
triple-negative tumors. AR positivity was significantly associated with lymphovascular invasion but not with other clinicopathologic parameters. There was a trend toward association between AR expression and PR expression.
Univariate survival analysis indicated that patients with AR-negative/ER-negative tumors had significantly worse overall survival and disease-specific survival than the patients with tumors showing other combinations of AR/ER status (i.e., AR-negative/ER-positive, AR-positive/ER-negative, or AR-positive/ER-positive). Notably, the study was performed using post-neoadjuvant IBC surgical specimens.
(more…)